UNDERWRITING AGREEMENT Aligos Therapeutics, Inc. [•] Shares of Common StockUnderwriting Agreement • June 28th, 2021 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
CONSULTING AGREEMENTConsulting Agreement • June 28th, 2021 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This CONSULTING AGREEMENT is made and entered into as of June 17, 2021 (the “Effective Date”) by and between ALIGOS THERAPEUTICS, INC., a Delaware corporation having a principal place of business at 1 Corporate Drive, 2nd Floor, South San Francisco, CA 94080 (“Aligos”) and Kathleen Sereda Glaub, an individual with an address of 1050 Lee Avenue, San Leandro, CA 94577 (“Consultant”). Aligos and the Consultant may be referred to herein individually as “Party” or collectively, as “Parties.”
